Berlin, Germany, and Nevada, USA, March 16, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today that Mrs. Barbara von Frankenberg has joined MagForce as Vice President Communications & Investor Relations. Barbara von Frankenberg will manage Magforce’s relations with investors and analysts in Europe and in the U.S. Prior to joining MagForce, Barbara von Frankenberg spent 16 years as Investor Relations Manager, holding senior roles with publicly listed high-tech companies.
“Barbara von Frankenberg is a highly dynamic executive with more than 15 years of experience in finance and communication, making her an excellent addition to our team. She will be one of the key liaisons between MagForce and the investment community and she will also manage the Company’s Corporate Communications function”, said Ben Lipps, CEO of MagForce.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group’s proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
